Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery
Exalpha Biologicals, Inc.

HLA-DR FITC

  • Product Code: 0DR2
  • Size: 100 Tests
  • Price (USD): $169

Cat #

0DR2		 Quantity:      

Data Sheet

Product Name

HLA-DR FITC

Synonyms

HLA-DR* FITC

Host/Source

Mouse

Clone

423L

Isotype

IgG2a

Product Type

Single-Color Reagent

Applications

Flow Cytometry

Purification

Protein A/G Chromatography

Size

100 Tests

Price (USD)

$169

Background

HLA-DR is used for the identification of human B cell and T cell subsets associated with approximately 10% of peripheral blood lymphocytes 28-34,000 M.W. surface antigen, and is present in low density on monocytes and macrophages.

Immunogen

HLA-DR=Derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human lymphoblastoid B-cell line RPMI 8866

Formulation

Provided as sterile filtered solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein

Customer Storage

Product should be stored at 4-8ºC. DO NOT FREEZE

Product Image

Image Legend

Peripheral blood lymphocytes stained with Exalpha’s HLA-DR PE Conjugated Antibody (Cat. No. 0DR4).

Database Links:

SwissProtP04233Human

References

1. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. Gerrard T.L., Dyer D.R., Mostowski H.S., J. Immunol. 1990 June, 1;144(12): 4670-4. 2. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. Karp D.R., Teletski C.L., Jaraquemada D., Maloy W.L., Coligan J.E., Long E.O., J. Exp.. Med. 1990 March ;171(3):615-28. 3. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Hu K.Q., Vierling J.M., Siddiqui A., Proc. Natl. Acad. Sci. USA 1990 SEPT.; 87(18):7140-4. 4. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C., Blakolmer K., McGlave P., J. Exp. Med. 1990 Aug.: 172(2):509-2. 5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704. 6. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Raziuddin S., Nur M.A., al-Wabel A.A., Scand. J. Immunol. 1990 Feb.:31(2):139-45.


Product Specific References


This product has been used in:

1. Weidmann, A., et al, 'Proteolytic Cleavage of the Fusion Protein but Not Membrane Fusion Is Required for Measles Virus-Induced Immunosuppression In Vitro' Journal of Virology 2000, 74, , 1985-1993